{"groups":[{"description":"Patients receive isatuximab IV on days 1, 8, 15, and 22 of course 1 and on days 1 and 15 of subsequent courses. Treatment repeats every 28 days for 24 courses in the absence of disease progression or unacceptable toxicity.\n\nIsatuximab: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies","id":"FG000","title":"Treatment (Isatuximab)"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"43"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"19"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"24"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"43 participants were enrolled of which 35 were eligible and analyzable."}